Larochelle P, Genest J, Kuchel O, Boucher R, Gutkowska Y, McKinstry D
Can Med Assoc J. 1979 Aug 4;121(3):309-16.
Seven patients with essential hypertension and seven patients with hypertension associated with renal artery stenosis received captopril (SQ 14225), an inhibitor of angiotensin I converting enzyme. There was a significant reduction in mean blood pressure, from 176/113 +/- 4/3 mm Hg during the control period to 140/90 +/- 5/3 mm Hg during captopril administration. Five patients received captopril alone and nine patients needed hydrochlorothiazide in addition to control their blood pressure. Captopril produced a significant increase in peripheral plasma renin activity. When measured 12 hours after the administration of captopril the angiotensin I converting enzyme activity was found to be similar to that during the control period even though the blood pressure was at or near normal. These findings indicate that although captopril is an effective antihypertensive agent, its action does not depend only on inhibition of plasma angiotensin I converting enzyme activity.
7例原发性高血压患者和7例肾动脉狭窄相关性高血压患者接受了血管紧张素I转换酶抑制剂卡托普利(SQ 14225)治疗。平均血压显著降低,从对照期的176/113±4/3毫米汞柱降至卡托普利给药期间的140/90±5/3毫米汞柱。5例患者单独接受卡托普利治疗,9例患者除卡托普利外还需要氢氯噻嗪来控制血压。卡托普利使外周血浆肾素活性显著升高。在卡托普利给药12小时后测量发现,尽管血压处于或接近正常水平,但血管紧张素I转换酶活性与对照期相似。这些发现表明,尽管卡托普利是一种有效的抗高血压药物,但其作用并不仅取决于对血浆血管紧张素I转换酶活性的抑制。